From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
Toxicity | G1 | G2 | G3 | G4 | Total |
---|---|---|---|---|---|
Allergic rhinitis | 2 | 1 | 0 | 0 | 3 |
Alopecia | 2 | 0 | 0 | 0 | 2 |
ALT 1 | 1 | 0 | 1 | 0 | 2 |
Anorexia | 2 | 4 | 0 | 0 | 6 |
AST 2 | 1 | 0 | 0 | 0 | 1 |
Bilirubin | 1 | 0 | 0 | 0 | 1 |
Cardiac ischemia | 0 | 0 | 1 | 0 | 1 |
Chest tightness | 1 | 0 | 0 | 0 | 1 |
Constipation | 4 | 4 | 0 | 0 | 8 |
Dehydration | 0 | 0 | 1 | 0 | 1 |
Diarrhea | 5 | 2 | 1 | 0 | 8 |
Distension | 0 | 0 | 1 | 0 | 1 |
Dizziness | 2 | 0 | 0 | 0 | 2 |
Dry mouth | 1 | 0 | 0 | 0 | 1 |
Dry skin | 1 | 0 | 0 | 0 | 1 |
Dysphagia | 1 | 0 | 0 | 0 | 1 |
Dyspnea | 2 | 2 | 6 | 0 | 10 |
Edema | 12 | 1 | 0 | 0 | 13 |
Fatigue | 5 | 3 | 5 | 0 | 13 |
Fever (no neutropenia) | 1 | 0 | 0 | 0 | 1 |
Flushing | 1 | 0 | 0 | 0 | 1 |
Hand-foot syndrome | 1 | 0 | 0 | 0 | 1 |
Hemoglobin | 1 | 2 | 0 | 0 | 3 |
Hypocalcemia | 1 | 0 | 0 | 0 | 1 |
Hypokalemia | 2 | 0 | 2 | 0 | 4 |
Hypomagnesemia | 1 | 0 | 0 | 0 | 1 |
Insomnia | 2 | 5 | 1 | 0 | 8 |
Mood alteration | 0 | 1 | 0 | 0 | 1 |
Mucositis | 4 | 0 | 0 | 0 | 4 |
Nausea | 4 | 6 | 1 | 0 | 11 |
Neuropathy (sensory) | 3 | 2 | 0 | 0 | 5 |
Neutrophils | 0 | 2 | 1 | 0 | 3 |
Ocular surface disease | 1 | 1 | 1 | 0 | 3 |
Ocular/visual | 2 | 0 | 0 | 0 | 2 |
Pain | 12 | 6 | 1 | 0 | 19 |
Palpitations | 1 | 0 | 0 | 0 | 1 |
Platelets | 1 | 0 | 0 | 0 | 1 |
Pleural effusion | 1 | 0 | 0 | 0 | 1 |
Pruritis | 1 | 0 | 0 | 0 | 1 |
Rash | 6 | 0 | 0 | 0 | 6 |
Rigors/chills | 2 | 0 | 0 | 0 | 2 |
Sinus tachycardia | 1 | 0 | 0 | 0 | 1 |
Somnolence | 3 | 0 | 0 | 0 | 3 |
Sweating | 1 | 0 | 0 | 0 | 1 |
Taste alteration | 5 | 4 | 0 | 0 | 9 |
Upper respiratory infection | 1 | 0 | 0 | 0 | 1 |
Voice change | 2 | 0 | 0 | 0 | 2 |
Vomiting | 2 | 2 | 0 | 0 | 4 |
Watery eye | 1 | 0 | 0 | 0 | 1 |